Renalytix AI (RNLX)
(Real Time Quote from BATS)
$0.31 USD
+0.01 (3.78%)
Updated Jul 23, 2024 02:06 PM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Renalytix AI PLC Sponsored ADR falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 25 | 41 | 65 | 14 |
Receivables | NA | 1 | 1 | 1 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 2 | 1 | 1 |
Total Current Assets | NA | 27 | 45 | 67 | 15 |
Net Property & Equipment | NA | 1 | 3 | 2 | 2 |
Investments & Advances | NA | 1 | 3 | 9 | 2 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 2 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 0 | 0 | 0 |
Total Assets | NA | 31 | 50 | 79 | 21 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 4 | 5 | 0 | 0 |
Accounts Payable | NA | 3 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 5 | 5 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 16 | 12 | 7 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 7 | 8 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 2 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 24 | 19 | 7 | 5 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 186 | 164 | 150 | 70 |
Retained Earnings | NA | -178 | -133 | -87 | -53 |
Other Equity | NA | -1 | -1 | 8 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 7 | 31 | 71 | 16 |
Total Liabilities & Shareholder's Equity | NA | 31 | 50 | 79 | 21 |
Total Common Equity | 0 | 7 | 31 | 71 | 16 |
Shares Outstanding | 77.10 | 47.40 | 37.30 | 36.10 | 35.20 |
Book Value Per Share | 0.00 | 0.15 | 0.82 | 1.98 | 0.45 |
Fiscal Year End for Renalytix AI PLC Sponsored ADR falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 5 | 6 | 14 | 25 |
Receivables | NA | 1 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 2 | 1 |
Total Current Assets | NA | 6 | 8 | 16 | 27 |
Net Property & Equipment | NA | 0 | 1 | 1 | 1 |
Investments & Advances | NA | 1 | 1 | 1 | 1 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 9 | 11 | 20 | 31 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 4 | 3 | 5 | 4 |
Accounts Payable | NA | 5 | 3 | 3 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 5 | 8 | 7 | 9 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 15 | 14 | 15 | 16 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 5 | 5 | 6 | 7 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 20 | 19 | 21 | 24 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 195 | 190 | 188 | 186 |
Retained Earnings | NA | -205 | -197 | -188 | -178 |
Other Equity | NA | -2 | -2 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -11 | -8 | -1 | 7 |
Total Liabilities & Shareholder's Equity | NA | 9 | 11 | 20 | 31 |
Total Common Equity | 0 | -11 | -8 | -1 | 7 |
Shares Outstanding | 77.10 | 77.10 | 49.90 | 48.70 | 47.40 |
Book Value Per Share | 0.00 | -0.14 | -0.16 | -0.03 | 0.15 |